nach oben

Drugs

Erschienen in:

01.09.2012 | Editorial

Developing New Drugs for Diabetes and Cardiometabolic Disorders

A Changing Paradigm

verfasst von: Professor Andrew J. Krentz, Linda Morrow, Marcus Hompesch

Erschienen in: Drugs | Ausgabe 13/2012

Einloggen, um Zugang zu erhalten

Excerpt

The range of drugs now available for the treatment of diabetes is unprecedented.[1] However, all the current agents correct metabolic derangements partially at best. Besides their limited efficacy, especially in terms of long-term glycaemic control, most of the well established and novel glucose-lowering drug classes have safety and/or tolerability issues that often constrain their use. The long-recognized gulf that exists between evidence-based goals of therapy and their consistent achievement in routine clinical practice remains to be bridged.[2] …

Cefalu WT. Evolving treatment strategies for the management of type 2 diabetes. Am J Med Sci 2012; 343: 21–6PubMedCrossRef

Hoerger TJ, Segel JE, Gregg EW, et al. Is glycemic control improving in U.S. adults?. Diabetes Care 2008; 31: 81–6CrossRef

Chao EC. Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes. Core Evid 2012; 7: 21–8PubMedCrossRef

Mundil D, Cameron-Vendrig A, Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res 2012; 9: 95–108PubMedCrossRef

Krentz A, Hompesch M. Future drug treatments for type 2 diabetes. Treatment Strategies-Diabetes 2011; 3 (1): 41–9

No authors listed. Lessons from Lipitor and the broken blockbuster drug model. Lancet 2011; 378 (9808): 1976

Krentz AJ. Rosiglitazone: trials, tribulations and termination. Drugs 2011; 71 (2): 123–30PubMedCrossRef

Derosa G, Maffioli P. Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf 2012; 11: 459–71PubMedCrossRef

O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of Lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM Study. Obesity 2012; 20: 1426–36PubMedCrossRef

10.

Chugh PK, Sharma S. Recent advances in the pathophysiology and pharmacological treatment of obesity. J Clin Pharm Ther. Epub 2012 Mar 30

11.

Kramer I, Sauer T. The new world of biosimilars: what diabetologists need to know about biosimilar insulins. Br J Diabetes Vasc Dis 2010; 10: 163–71CrossRef

12.

No authors listed. Approval of biosimilars in the USA: dead ringers?. Lancet 2012 Feb 25; 379 (9817): 686

Titel: Developing New Drugs for Diabetes and Cardiometabolic Disorders
A Changing Paradigm
verfasst von: Professor Andrew J. Krentz
Linda Morrow
Marcus Hompesch
Publikationsdatum: 01.09.2012
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 13/2012
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/11635550-000000000-00000

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Developing New Drugs for Diabetes and Cardiometabolic Disorders

A Changing Paradigm

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 13/2012

Prevention of Venous Thromboembolism with New Oral Anticoagulants versus Standard Pharmacological Treatment in Acute Medically Ill Patients

Polymorphisms of Estrogen Receptors and Risk of Depression

Will Abuse-Deterrent Formulations of Opioid Analgesics Be Successful in Achieving Their Purpose?

Linagliptin

Reduced-Antigen, Combined Diphtheria, Tetanus and Acellular Pertussis Vaccine, Adsorbed (Boostrix®)

New Oral Anticoagulants